| Literature DB >> 35252213 |
Gustavo Ramirez-Calderon1, Giovanni Colombo1, Carlos A Hernandez-Bautista1, Veronica Astro1, Antonio Adamo1.
Abstract
Human pluripotent stem cells (hPSCs) constitute a valuable model to study the complexity of early human cardiac development and investigate the molecular mechanisms involved in heart diseases. The differentiation of hPSCs into cardiac lineages in vitro can be achieved by traditional two-dimensional (2D) monolayer approaches or by adopting innovative three-dimensional (3D) cardiac organoid protocols. Human cardiac organoids (hCOs) are complex multicellular aggregates that faithfully recapitulate the cardiac tissue's transcriptional, functional, and morphological features. In recent years, significant advances in the field have dramatically improved the robustness and efficiency of hCOs derivation and have promoted the application of hCOs for drug screening and heart disease modeling. This review surveys the current differentiation protocols, focusing on the most advanced 3D methods for deriving hCOs from hPSCs. Furthermore, we describe the potential applications of hCOs in the pharmaceutical and tissue bioengineering fields, including their usage to investigate the consequences of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) infection in the heart.Entities:
Keywords: cardiac development; cardiac differentiation; cardiac maturation; cardiogenesis; disease modeling; organoids; pluripotent stem cell (PSC)
Year: 2022 PMID: 35252213 PMCID: PMC8893312 DOI: 10.3389/fcell.2022.855966
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Schematic of cardiac development and 2D/3D culture methods for the derivation of human cardiac organoids. (A) Timeline of cardiac development in vivo. The blastocyst originates the primitive streak from which the mesodermal layer emerges. Cardiovascular progenitors migrate through the primitive streak to form the cardiac crescent at the embryo’s midline and generate the heart tube. Subsequently, heart tube looping and remodeling produce the final heart architecture. (B) Description of 2D GiWi differentiation protocol. hPSCs are treated with CHIR99021 (GSK3 inhibitor/Wnt activator) to induce primitive streak and mesoderm, followed by IWP2 (Wnt-inhibitor) treatment to trigger the cardiac commitment. The GiWi 2D protocol generates immature fetal-like hPSC-derived cardiomyocytes. (C) 3D self-assembly of human cardiac organoids begins with hPSCs aggregation in ultra-low attachment plates. However, only Drakhlis et al. used an additional hPSC aggregate encapsulation in Matrigel. (D) Hofbauer et al. implemented FGF2 and BMP4 throughout the mesoderm induction, cardiac mesoderm, and cardiomyocyte specification. Additionally, this method relies on Activin A (AA), CHIR99021, and LY294002 (PI3K- inhibitor) for mesoderm induction, IWP2, and retinoic acid for cardiac mesoderm induction. Additional co-culture with epicardial aggregates generates hCOs with chamber-like structures and three layers composed of epicardium, myocardium, and endocardium. (E) Lewis-Israeli et al. adopted a modified GiWi protocol by adding BMP4, AA, and CHIR99021 for mesodermal induction and Wnt-C59 (Wnt-inhibitor) for cardiac mesoderm formation. A subsequent CHIR99021 treatment triggers epicardial induction. These organoids develop chambers and vessel-like structures. (F) Drakhlis et al. described a GiWi protocol to generate hCOs with an inner and outer layer resembling the anterior and posterior foregut endoderm (brown color). These hCOs have a mid-myocardial layer without chamber-like structures and some epicardial-like cells (septum-transversum-like anlagen) in the outer layer. (G) Directed assembly of hCOs combines hPSC-derived cardiomyocytes with fibroblasts and endothelial cells in a hydrogel matrix surrounding two elastomeric poles. After hydrogel condensation, hCOs are mechanically or electrically stimulated or both to induce a mature-like phenotype.
Generation of hCOs by the self-assembly and the directed assembly methods.
| References | Cell source | Method | Platform | Applications | hCO features |
|---|---|---|---|---|---|
|
| hESCs and hiPSCs | Self-assembly | Round bottom ultra-low attachment 96-well plate, Matrigel-embedded | Modeling early cardiomyogenesis and genetic heart defects | HFOs including inner (anterior foregut endoderm-like), myocardial, and outer (posterior foregut endoderm-like) layers |
|
| hESCs and hiPSCs | Self-assembly | Round bottom ultra-low attachment 96-well plate, later co-culture with hPSC-derived epicardial clusters | Modeling early cardiomyogenesis (HAND1-KO hCOs) and developmental injury | Cavity-containing hCOs, including endocardial and myocardial layer. Outer epicardial layer obtained by co-culture with hPSC-derived epicardial clusters |
|
| hESCs and hiPSCs | Self-assembly | Round bottom ultra-low attachment 96-well plate | Modeling early cardiomyogenesis and disease condition | Cavity-containing hCOs, including endocardial, myocardial and epicardial layers |
|
| hESCs and hiPSCs | Self-assembly | Micropatterned 6-well plate | Developmental drug toxicity assays (pregnancy risk drugs) | hCOs include a central area of CMs with a perimeter of myofibroblasts |
|
| (hESCs and hiPSCs) hPSC derived-CMs and human foreskin fibroblasts | Directed assembly | Casting in medical-grade type I collagen hydrogels, later mechanical stimulation by dynamic stretching between two elastomeric pillars | Advance CMs maturation and modeling heart failure | EHTs with fetal-like CMs |
|
| hiPSCs | Directed assembly | Casting in fibrin hydrogels, later mechanical stimulation by dynamic stretching between two elastomeric pillars and electrical stimulation | Improving hPSC-derived CM maturation and modeling pathological cardiac hypertrophy (via endothelin-1 treatment) | EHT with extensive T-tubule network and mature calcium handling |
|
| hESCs and hiPSCs | Directed assembly | Heart-dyno: casting in collagen I and Matrigel hydrogels in a well insert containing two elastomeric pillars | Screening for cardiac maturation, cardiomyocyte proliferation, and drugs to treat SARS-CoV-2-induced cardiac dysfunction | hCOs with fatty acid oxidation metabolism, DNA damage response, and cell cycle arrest |